Management of psychiatric disorders in patients infected with human immunodeficiency virus.
Psychiatric disorders increase the risk of acquiring human immunodeficiency virus (HIV) and increase morbidity from HIV-related illness by impeding treatment. The response to highly active antiretroviral therapies is impaired by poor patient adherence, a substantial component of which is related to mental illness and substance use disorders. The recognition of psychiatric disorders in most HIV clinics is an issue of utmost importance. We outline diagnostic and treatment issues for major depression, bipolar disorder, personality disorder, substance use disorders, and demoralization as seen in patients with HIV. Our experience at the Johns Hopkins Moore (HIV) Clinic has led us to conclude that treatment of these disorders greatly improves patient adherence to treatment and outcomes of HIV infection.
Angelino
A F
AF
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Treisman
G J
GJ
D000928:Antidepressive Agents / Q000008:administration & dosage; D014150:Antipsychotic Agents / Q000008:administration & dosage; D023241:Antiretroviral Therapy, Highly Active; D001714:Bipolar Disorder / Q000150:complications / Q000523:psychology / Q000628:therapy; D003866:Depressive Disorder / Q000150:complications / Q000523:psychology / Q000628:therapy; D004347:Drug Interactions; D015658:HIV Infections / Q000150:complications* / Q000523:psychology* / Q000628:therapy; D006801:Humans; D001523:Mental Disorders / Q000150:complications* / Q000523:psychology / Q000628:therapy*; D010349:Patient Compliance; D010554:Personality Disorders / Q000150:complications / Q000523:psychology / Q000628:therapy; D019966:Substance-Related Disorders / Q000150:complications / Q000523:psychology / Q000628:therapy
D000928:Antidepressive Agents; D014150:Antipsychotic Agents